Annual Report 2006 - Boehringer Ingelheim

In the area of HIV/AIDS therapy, we have for
years considered it our duty to undertake the
special social task of making our medication
viramune® available to patients who would
otherwise receive an inadequate supply of
medicine. Through our donation programme
we support activities that clearly reduce the risk
of transmission of HIV from mother to child
during birth using an antiretroviral therapy. For
this purpose we make our AIDS medication
viramune® available free of charge. In 2006,
we in addition reduced the price for viramune®
for some developing countries and within the
framework of the Accelerating Access Initiative
(AAI) programme we offer these countries considerable
price reductions. Furthermore, we have
in the meantime granted seven manufacturing
licences that allow generic production in the
developing countries concerned.
At the same time in 2006, we sought through
numerous clinical studies with aptivus® and
viramune® to gain further insights into the
treatment and therapy of AIDS.
Another given for our social responsibility as
a company is, where possible, to encourage
and support the voluntary commitment of our
employees. Many of our employees engage
voluntarily in their free time in social projects
and make a decisive contribution where help
is called for.
Results from operations,
financial position and
net assets
Results from operations
Independent market data show that Boehringer
Ingelheim again grew faster than the overall
market in 2006. We thereby gained market share
for the seventh consecutive year. This success
was all the more remarkable, as Boehringer
Ingelheim achieved this growth essentially with
its own resources, i.e. with products from its own
research. According to current market data,
Boehringer Ingelheim ranks 15th among the
world’s largest pharmaceutical companies, with
a market share of 2 %.
Boehringer Ingelheim increased its net sales by
10.9 % in 2006 to EUR 10,574 million. Exchange
rate movements, compared to the previous period
2005, had a slightly negative impact (-1 %) on
this development. When analysing our growth, it
must be noted that changes in the consolidation
were negligible. The acquisition of the product
zantac® in the USA took place at the end of
2006 and has not yet affected our turnover
development.
Boehringer Ingelheim is divided into the businesses
Human Pharmaceuticals and Animal
Components of growth in net sales (as %) 2006 2005 2004 2003 2002
Price/quantity/new introductions 12.1 17.4 16.1 7.8 10.1
Acquisition and sale of businesses –0.3 –0.5 –0.5 –0.2 7.1
Currency effect –0.9 0 –5.1 –10.2 –4.0
Group Management Report 107